Facebook Instagram X-twitter Linkedin Youtube Spotify Apple

Duchenne News Tags: Satellos Bioscience

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences BioMarin Pharmaceuticals Capricor Therapeutics Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FDA FibroGen Italfarmaco ITF Therapeutics Novartis NS Pharma PepGen Percheron Therapeutics Pfizer Pliant Therapeutics Precision Biosciences PTC Therapeutics REGENXBIO Roche Santhera Sarepta Therapeutics Satellos Bioscience Secretome Therapeutics Solid Biosciences Upsher-Smith Wave Life Sciences
October 7, 2026

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

At the end of September, Satellos Biosciences announced that enrollment is complete for BASECAMP, a Phase 2 clinical trial evaluating forazapadin, a drug candidate designed to support muscle repair and...
Read More
July 3, 2026

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

On June 29, 2026, Satellos Bioscience Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAT-3247 for the treatment of Duchenne. Please read...
Read More
February 12, 2026

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

On February 12, 2026, Satellos Bioscience Inc, announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for...
Read More